Polymerase chain reaction compared with dot blotting for the determination of N-myc gene amplification in neuroblastoma.
The magnitude of N-myc amplification (NMA) influences the treatment strategy of localized neuroblastomas. Reliable assays are therefore needed for all types of tumor samples. The aim of this comparative study of 119 tumor samples was to determine whether a polymerase chain reaction (PCR)-based assay could replace the current dot blot assay as a routine and reliable means of determining NMA. The 2 assays exhibited comparable sensitivity and were completely concordant for samples containing at least 20% neuroblastoma cells. In their present state, both assays remain semi-quantitative since an absolute quantification of the N-myc copy number in clinical samples is limited by uncertainty about the amplification level of reference cell lines and by the estimation of the proportion of malignant cells. However, PCR offers several advantages over dot blotting, such as feasibility on minute samples, simplicity, standardization, rapidity and cost effectiveness.
de Cremoux
P
P
Section Médicale, Institut Curie and Université Paris 7, France.
Thioux
M
M
Peter
M
M
Vielh
P
P
Michon
J
J
Delattre
O
O
Magdelenat
H
H
D003362:Cost-Benefit Analysis; D004273:DNA, Neoplasm / Q000032:analysis*; D005784:Gene Amplification; D016259:Genes, myc; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D006801:Humans; D009447:Neuroblastoma / Q000235:genetics*; D009693:Nucleic Acid Hybridization; D016133:Polymerase Chain Reaction / Q000191:economics / Q000592:standards; D012680:Sensitivity and Specificity
D004273:DNA, Neoplasm; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases